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ABSTRACT 
EXTRACTION AND CLASSIFICATION OF DRUG-DRUG INTERACTION FROM 
BIOMEDICAL TEXT USING TWO-STAGE CLASSIFIER 
 
by 
Majid Rastegar-Mojarad 
The University of Wisconsin-Milwaukee, 2013  
Under the Supervision of Professor Rashmi Prasad 
 
 
One of the critical causes of medical errors is Drug-Drug interaction (DDI), which occurs 
when one drug increases or decreases the effect of another drug. We propose a machine 
learning system to extract and classify drug-drug interactions from the biomedical 
literature, using the annotated corpus from the DDIExtraction-2013 shared task 
challenge. Our approach applies a two-stage classifier to handle the highly unbalanced 
class distribution in the corpus. The first stage is designed for binary classification of 
drug pairs as interacting or non-interacting, and the second stage for further classification 
of interacting pairs into one of four interacting types: advise, effect, mechanism, and int. 
To find the set of best features for classification, we explored many features, including 
stemmed words, bigrams, part of speech tags, verb lists, parse tree information, mutual 
information, and similarity measures, among others. As the system faced two different 
classification tasks, binary and multi-class, we also explored various classifiers in each 
stage. Our results show that the best performing classifier in both stages was Support 
Vector Machines, and the best performing features were 1000 top informative words and 
part of speech tags between two main drugs. We obtained an F-Measure of 0.64, showing 
a 12% improvement over our submitted system to the DDIExtraction 2013 competition.  
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1- 1 Motivation 
One of the important causes of medical errors is Drug-Drug Interactions (DDI). Some 
studies estimate that medical errors result in around 44,000 and 98,000 deaths per year in 
the United States[1], and that 7,000 of those deaths are due to medication-related errors 
[2]. Other reports have noted similar patterns around the globe [1], [3]–[5] so that this 
problem is not unique to the United Sates. The good news, however, is that most of these 
medication-related errors are preventable. A report in Australia [6] mentioned that 75% 
of hospital admissions related to medication errors are preventable. 
Potential drug-drug interactions, defined as the co-prescription of two or more drugs that 
are known to interact, are a significant source of preventable drug-related harm (i.e., 
adverse drug events (ADEs)) [7]. A recent review estimates that clinically important 
events that are attributable to potential drug-drug interaction exposure occur in 5.3% - 
14.3% of inpatients, and are responsible for 0.02% to 0.17% of the 129 million 
emergency department visits that occur each year [8]. Gurwitz et al, in a cohort study of 
adverse drug events, reported that 13.3% of preventable errors leading to an ADE 
involved the co-prescription of drugs for which interactions are well known [9]. Nearly 
7% (23/338) of the ADEs experienced by residents of two academic nursing homes over 
a nine-month period were attributable to DDIs [10]. Sixteen cohort and case-control 
studies reported an elevated risk of hospitalization in patients exposed to DDIs [11]. 
Failure to properly manage a DDI is a medical error, and the Institute of Medicine has 
noted that a lack of drug knowledge is one of the most frequent proximal causes of such 
errors [12]. Indeed, health care providers often have inadequate knowledge of what drug 
interactions can occur, of patient specific factors that can increase the risk of harm from 
  
3 
an interaction, and of how to properly manage an interaction when patient exposure 
cannot be avoided [11], [13]. 
Unfortunately, there is no single complete and authoritative source of DDI knowledge 
[14]. Rather, there are multiple sources, each tasked with extracting, evaluating, and 
staying up-to-date with pertinent DDIs reported in the literature, and drug product 
labeling [15]. The following is a list of the resources that currently provide this 
information: 
1- DrugBank [15]: is a database containing bioinformatics and cheminformatics 
information. It combines detailed information about drugs and their targets (such 
as sequence, structure). 
2- DailyMed 1 : Through the DailyMed website, the U.S. National Library of 
Medicine provides downloadable information about marketed drugs, including 
FDA labels (package inserts). Package inserts are authoritative resources which 
healthcare professionals can rely on for warnings and precautions about the 
potential dangers of prescribing a drug, and the potential interactions and side-
effects that a drug may have. 
3- National Drug File - Reference Terminology (NDF-RT) [16], [17]: is produced 
by the U.S. Department of Veterans Affairs, Veterans Health Administration 
(VHA). It provides information about drug characteristics, including ingredients, 
chemical structure, dose form, physiologic effect, mechanism of action, drug 
interaction, and related diseases. 
                                                
1 http://dailymed.nlm.nih.gov/dailymed/about.cfm 
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4- Micromedex2 (Drug-Reax): is a US drug compendium. It is commonly used by 
health professionals to obtain information on drug interactions. It further 
classifies the drug-drug interactions into different categories, such as major, 
moderate, and minor, based on their severity. 
5- Express Scripts DRUG DIGEST Check Interactions3: is a database including 
more than 5,000 drugs and herbals and 11,500 potential interactions. 
6- Medscape for WebMD4: provides information on interactions resulting from 
combination of drugs, herbals and supplements. 
Despite the availability of several such resources providing information on drug 
interactions, there are bottlenecks in fully and effectively utilizing them. Some such as 
DrugBank, are simply not practical or useful for prescribers to review at the point–of-
care, while others, such as product labels, are often complete and updated, even though 
they are often reviewed at the point of care. 
The bigger issue, however, is the inconsistency of information found in these resources, 
and sometimes, between them. Our own study [18] demonstrates this for package inserts. 
Manual review by a clinical pharmacologist of 100 randomly selected potential 
interactions out of more than 300,000 automatically extracted interactions revealed that 
40% were genuinely inconsistent. Vitry [19] studied the consistency and grading of major 
drug interactions for 50 drugs in four leading international drug interaction compendia: 
the drug interactions appendix of the British National Formulary, the interaction 
                                                
2 http://www.micromedex.com/ 
3 http://www.drugdigest.org/ 
4 http://reference.medscape.com/drug-interactionchecker 
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supplement in the French Drug Compendium Vidal, and two US drug interaction 
compendia, Drug Interaction Facts and Micromedex. They analyzed major interactions 
for a list of 50 drugs in all four compendia and found that 14-44% of interactions are not 
mentioned in at least one resource. The authors also noted inconsistencies in the severity 
grading system between the compendia. Shah et al. [20] found that the drug-drug 
interaction knowledge databases used for clinical decision support systems are not 
consistent with official package labels, causing spurious warnings and inaccurate 
information. They highlighted the importance of the accuracy and completeness of drug 
databases. Li et al. [21] showed that the top commercial drug interaction databases take 
approximately one month to update with new information. 
The dynamic nature of drug knowledge, combined with the enormity of the biomedical 
literature, makes the task of collecting and maintaining up-to-date information on drug 
interactions extremely challenging and time-consuming. Therefore, there is a strong need 
to approach this task with automated methods, supplemented with human effort. Natural 
language processing (NLP) and information extraction methods for identifying and 
extracting DDIs have been receiving increased attention in the last few years, and several 
attempts have already been made to develop methods for this task, showing good 
potential for success, although there remains much room for improvement. 
The goal of this thesis is to design, implement, and evaluate a method for extracting and 
classifying drug-drug interactions from biomedical text using machine learning 
algorithms and NLP methods. For this purpose, we participated in a shared task 
challenge, the DDIExtraction 2013 Shared Task Challenge, that provided a benchmark 
dataset for drugs and drug-drug interactions. Participating in the shared task allowed us to 
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directly compare our system with those of several others participating in the challenge, 
and also, since it took place in 2013, assured us that this task poses an ongoing challenge 
to the current research community. The DDIExtraction 2013 challenge was a follow up to 
the first challenge organized for this shared task in 2011. In what follows, we describe the 
design of both of these challenges. Methods developed by the participants of the 
challenges, along with their results, are discussed in Chapter 2. 
1-2 Benchmark datasets for Information Extraction of Drug-Drug Interactions 
Two shared tasks, DDIExtraction-2011 and DDIExtraction-2013, provided two 
benchmark datasets for drug-drug interactions.    
1-2-1 The 1st Drug-Drug Interaction Extraction 2011 Shared Task Challenge 
(DDIExtraction-2011) 
In 2011, the first shared task challenge for DDI extraction, DDIExtraction-2011 [22], 
invited participants to develop automatic methods to extract DDIs. Ten teams participated 
in the challenge. The task focused on the identification of all possible pairs of interacting 
drugs in sentences, without specifying anything further about the interactions. The 
organizers provided an annotated corpus for training and testing and evaluated the 
participants’ systems on the test portion of the corpus. The corpus was drawn from 579 
documents about DDIs from DrugBank. After choosing the documents, the UMLS 
MetaMap Transfer [23] was applied to automatically identify drug names in the 
sentences, and sentences containing two or more drugs were then manually annotated by 
a researcher with a pharmaceutical background. Of the total of 5,806 sentences across the 
579 documents, 2,044 sentences were found to contain at least one DDI, and there were a 
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total of 3,160 DDIs in the corpus. Figure 1-1 illustrates one sentence of this corpus 
annotated with DDIs, presented in the unified XML format [24]: <sentence>, <entity>, 
and <pair> element tags mark up the raw sentence text, drug entities found in the 
sentence, and DDIs found in the sentence, respectively. Word-based offsets are used to 
link drug entities to the raw text. The “interaction” attribute in the <pair> element 
encodes the classification of a drug pair as “true” (i.e., interacting) or “false” (i.e., non-
interacting). 
 
Figure 1-1: Annotations of one sentence from the DDIExtraction-2011 corpus.  
1-2-2 The 2nd Drug-Drug Interaction Extraction 2013 Shared Task Challenge 
(DDIExtraction-2013) 
The second shared task challenge on drug-drug interactions, DDIExtraction-2013 [25], 
was offered as part of the 2013 International Workshop on Semantic Evaluation 
(SemEval-2013).5 There were 14 participating teams for the task. In contrast to the 2011 
challenge, the 2013 challenge also included the task of drug name recognition and 
classification, although it was set up as distinct from the task of DDI extraction, which 
was itself an extension of the 2011 task. Thus, the following two subtasks were offered:  
                                                
5 http://www.cs.york.ac.uk/semeval-2013/ 
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1. Recognition and classification of drug names 
2. Extraction and classification of drug-drug interactions 
In addition to extracting drug-drug interactions in the second task, the task called for their   
further classification into one of five different classes: advise, effect, mechanism, int, and 
none. The task emphasized the importance of recognizing what is being asserted about a 
drug interaction instead of just identifying an interaction. The five classes are defined 
below, with examples provided for illustration: 
1. Advise: the sentence notes a recommendation or advice related to the concomitant 
use of the two drugs (e.g., “… UROXATRAL should NOT be used in 
combination with other alpha-blockers.”); 
2. Effect: the sentence states the effect of the drug interaction, including 
pharmacodynamic effect or mechanism of interaction (e.g., “Quinolones may 
enhance the effects of the oral anticoagulant, warfarin, …”); 
3. Mechanism: the sentence describes a pharmacokinetic mechanism (e.g., 
“Grepafloxacin is a competitive inhibitor of the metabolism of theophylline.”). 
4. Int: the sentence mentions a drug interaction but doesn’t provide any additional 
information about its nature (e.g., “The interaction of omeprazole and 
ketoconazole has been established.”). 
5. None: the sentence does not show an interaction between the two drugs; 
As the goal of our work, and this thesis, is to focus on the extraction and classification of 
drug-drug interactions, we participated in the second sub-task of the challenge.  
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The training corpus provided in the challenge contains 142 Medline abstracts on the 
subject of drug-drug interactions, and 572 documents describing drug-drug interactions 
from the DrugBank database. The corpus includes 6976 sentences annotated with four 
types of pharmacological entities and five types of DDIs, as described above. Figure 1-2 
illustrates annotations of drug entities and drug interactions for three sentences in a 
document. All possible drug-pairs in a sentence are annotated as either “true”, for an 
interacting drug-pair, or “false”, for a non-interacting drug pair. Each annotated drug pair 
is treated as an instance for training, and from the perspective of training, drug-pairs 
annotated as “true” belong to the positive class (or the set of positive instances), while 
those annotated as “false” belong to the negative class (or the set of negative instances). 
Positive instances are further annotated as one of the four interacting types described 
above, namely, advise, effect, mechanism, int.  
  
Figure 1-2: Annotations of three sentences from a document in the DDIExtraction-2013 corpus.  
 
Table 1-1 shows the number of instances for each of the five DDI types in the training 
set, grouped further into positive and negative classes. We note again that each instance is 
associated with a single pair of drugs. For example, a sentence with 4 drugs contains 6 
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instances, corresponding to 6 distinct drug pairs with a potential for interaction. Thus, 
while the entire training corpus contains 6976 sentences, the number of training instances 
as shown in the Table is much higher, i.e., 24891 instances. 
The test set for the task, used only during the evaluation period in the challenge, includes 
33 Medline abstracts and 158 DrugBank documents, containing 1299 sentences and 5519 
drug pairs (instances). As the test set had not been made available until the time of 
writing of this thesis, the experiments we conducted after the challenge, and report on 
here, are done using only the training data, in particular by splitting the training data into 
a training set (90%) and a test set (10%). 
Table 1-1: Distribution of drug-pair instances for each class in the DDIExtraction-2013 corpus. Classes are 
categorized in two super classes: positive and negative, to indicate presence and absence of interaction, 
respectively.  
Type DrugBank Medline Total 
Positive 
Advise 819 8 827 
Effect 1548 152 1700 
Mechanism 1260 62 1322 
Int 178 10 188 
Negative None 
(non-interacting drug-pairs) 
19479 1375 20854 
Total 23,284 1607 24891 
 
In this thesis, we describe our system for extracting and classifying drug-drug 
interactions from biomedical text, utilizing the training corpus provided for the 
DDIExtraction-2013 shared task challenge. Our approach combines machine-learning 
methods with rules for post-processing. A key feature of our machine-learning approach 
is that it is specifically designed to handle the highly unbalanced class distribution 
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observed in the data, via the use of a two-stage classifier. In addition to a variety of 
features exploited for the classifier, we also developed a set of post-processing rules, with 
a different set of rules applied after each stage of classification. Although we applied 
weighted SVM as the classifier for the DDI-2013 competition, here we report additional 
experiments with several other classifiers to assess if a classifier other than SVM may be 
better suited to the task. Our experiments indicate that SVM is the best fit for both stages. 
We also describe our experiments with exploring additional features for the classifier, 
specifically those exploiting syntactic information obtained from sentence parse trees. 
Finding effective features and utilizing them in the system resulted in improving the F-
measure by 12%, when compared to the results obtained in the competition.   
The thesis is organized as follows. In Chapter 2, we describe the related work on drug 
named entity recognition as well as DDI extraction and classification, particularly 
discussing all systems that participated in the DDIExtraction 2011 and 2013 challenges. 
In Chapter 3, we describe our method, the classifiers used in each stage, their features, 
and post processing. In Chapter 4, we present the evaluation and results. Error analysis, 
discussion, and future work are presented in Chapter 4.  
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2-1 Introduction 
In this chapter, we review the studies that have been conducted to extract and classify 
drug interactions from text. Most studies on this problem have been carried out as part of 
the DDIExtraction-2011 and DDIExtraction-2013 challenges, so we focus on these here. 
First, however, we review recent Drug Named Entity Recognition methods, since their 
outputs are vital for DDIExtraction systems, although our own work uses gold standard 
annotations of drug names in the corpus, provided as part of the challenge. 
2-2 Drug Named Entity Recognition 
The first step for extracting Drug-Drug interactions from text involves detecting drug 
names. Needless to say, performance of Drug Named Entity Recognition (NER) system 
has an impact on the performance of DDI extraction systems. Three common approaches 
for Drug NER are dictionary-based, rule-based and machine learning methods.6 For 
creating a dictionary that contains a list of drug names and their property, DrugBank [15] 
is a useful source. It is an open access, web-enabled database that contains structural, 
physicochemical, pharmacological and target information of approximately 4300 
substances, of which 1177 are approved drugs. Another useful resource for drugs is Daily 
Med, which presents all drug labels (Package Inserts). It is created by the U.S. National 
Library of Medicine. In fact, the main goal of package inserts is to provide useful 
information about drugs to physicians and help them to prescribe drugs appropriately. 
                                                
6 When comparing the performance these methods it is worth keeping in mind that some of these methods 
were designed for detecting general chemical names, which is a harder task rather than drug NER and 
therefore a possible reason for the poorer performance. 
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Several tools, based on machine learning techniques, have been developed to identify 
drug names in text. One of them is cTAKES [26], an open source system to extract 
medical information from clinical text. It has several components, including named entity 
recognition, which covers NER for drugs, in addition to other entity types. 
One of the recent studies for identifying and classifying drug names is done by Segura et 
al [27]. Their rule-based system combines information from several resources such as 
UMLS MetaMap Transfer, World Health Organization, and International Nonproprietary 
Names Program. Besides identifying pharmaceutical substances, the system is able to 
detect drug names. 
Hettne et al. [28] have developed a dictionary that detects small molecules and drugs. 
They combined information from UMLS, MeSH, ChEBI, DrugBank, KEGG, HDMB and 
ChemlDplus.  They also used rule-based term filtering. They report a precision of 0.67 
and recall of 0.40. 
ChemSpot [29] is a Named Entity Recognition tool for identifying mentions of chemicals 
in text. It detects trivial names, drugs, abbreviations, molecular formulas and IUPAC 
entities. It uses CRF (Conditional Random Fields) and a dictionary-based approach. It 
obtained 68.1% F-measure on the SCAI corpus. There were five systems [25] 
participating in the Drug NER task in DDIExtraction-2013, variously using dictionary 
based and machine learning techniques.  
2-3 Drug-Drug Interactions 
As we noted earlier, most DDI-Extraction studies were conducted as part of the DDI-
Extraction 2011 and 2013 challenges. In this section, we review these studies. 
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2-3-1 DDIExtraction 2011  
Segura et al [30] report one of the first attempts to extract drug-drug interactions from the 
biomedical literature. They used a hybrid method that combines shallow parsing and 
syntactic simplification with pattern matching. The UMLS MetaMap tool (MMTx) is 
used to provide shallow syntactic parsing and a set of domain-specific lexical patterns 
were developed to extract DDIs. Separately, in later work, they utilized a supervised 
machine learning approach to identify DDIs [31],  while also creating a DrugDDI corpus 
for evaluating their approach. Their SVM classifier achieved 0.51 precision, 0.72 recall 
and F-measure of 0.60. 
Mata et al [32] developed a Machine Learning system for DDI extraction that achieved 
an F-measure of 0.4702. For developing the system, they used around 600 features, such 
as keyword before first drug, keyword after second drug, keyword between drugs, and 
number of words and phrases between drugs. They explored four classification 
algorithms: RandomForest, NaïveBayes, SMO, and multiBoosting. Their best result 
comes from RandomForest. 
Garcia et al [33] built a Machine Learning system based on bag of words and pattern 
extraction. 1,010 words with a high gain ratio were collected and used as a “bag of 
words” feature, in addition to word categories to reflect the structure of the sentence, 
including subordinators, independent markers, appositions, coordinators, absolute, 
quantifiers, negations, etc. They also used Maximal Frequent Sequences (MFS) as a 
feature. A sequence is defined as an ordered list of elements, in this case, words. A 
sequence is maximal if it is not a subsequence of any other; that is, if it does not appear in 
any other sequence in the same order. All MFS from the training corpus were extracted, 
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with length between 2 and 7, and appearing in at least 10 sentences. Several classifiers 
were explored in this work, including Support Vector Machines, Decision Trees and 
multiple ensemble classifiers such as Bagging, MetaCost and Random Forests. Their best 
choice was Random Forest with 100 iterations and 100 attributes per iteration, with an F-
Measure of 0.5829.  
Thomas et al [34] have used Ensemble learning for DDI extraction. Their single best 
single classifier achieved an F-Measure of 0.63 and the best ensemble achieved 0.65. 
They used three kernel based approaches (APG, kBSPS, and SL) and case-based 
reasoning (Moara).   
Bjorne et al [35] presented a DDI system that explored both SVM and regularized least-
squares classifiers. They obtained 0.62 F-measure on DrugDDI. Minard et al [36] also 
presented a system based on SVM by using LIBSVM and SVMPerf tools. They reported 
a 0.5965 f-measure on DrugDDI.  
Chowdhury et al [33] participated in the DDIExtraction 2011 challenge and evaluated a 
range of new composite kernels for DDI. These kernels combine different combinations 
of mildly extended dependency tree (MEDT) kernel, phrase structure tree (PST) kernel, 
local context (LC) kernel, global context (GC) kernel and shallow linguistic (SL) kernel. 
The best result is an F-Measure of 0.6370 by combining MEDT, PST and GC kernels. 
They used the UMLS SPECIALIST lexicon tool to normalize tokens to avoid spelling 
variations and to provide lemmas. They also used dependency parse trees for 
corresponding sentences.  
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Karnik et al [37] presented a DDI extraction system that used all paths graph kernel. The 
system didn’t work well on DrugDDI corpus and it obtained a 0.16 F-measure. But F-
measure for a clinical pharmacokinetic DDI corpus was 0.658. 
2-3-2 DDIExtraction 2013 
In the 2013 challenge, the system with the highest F-Measure is proposed by the FBK-irst 
team [38]. Their system is a multi-phase relation extraction system. They used two 
separate phases for DDI extraction and classification. For DDI extraction, they removed 
less informative sentences and instances, and then trained a system on the remaining 
instances. A hybrid kernel classifier that contains a feature based kernel, a shallow 
linguistic kernel, and a Path-Enclosed Tree kernel is used in the first step. For 
classification of DDI, they trained 4 separate models for each class (one vs. all the other 
classes). 
The innovative part of this system is detecting “less informative sentences”, where a 
sentence is considered less informative if all drugs in a sentence fall under the scope of a 
negation cue (such as not). A negation detector system (focused on a limited set of 
negation cues, such as no, n’t and not) is used to identify and filter the less informative 
sentences. The remaining sentences are classified with the SVM Light-TK toolkit 
(Moschitti, 2006)[39], utilizing the Charniak-Johnson reranking parser [40], a self-trained 
biomedical parsing model [41], and the Stanford parser [42]. On the DDI-DrugBank test 
dataset, they obtained 0.68 F-Measure and on the DDI-Medline test dataset, 0.40 F-
Measure. 
The WBI-DDI team [43] presented a two-step system, like the first system in this 
competition, that splits the step for extracting DDIs step from that of classifying DDIs. 
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For extracting DDIs, an ensemble approach is applied, which combines the output of five 
different classifiers via majority voting. The framework for this ensemble approach is 
provided in [44].  All-Paths Graph [45], shallow linguistic [46], subtree [47], subset tree 
[48], and spectrum tree [49] method are the classifiers used in the ensemble method. Each 
classifier uses different sets of features, but most of them used part-of-speech tags, 
constituent parse tree, and dependency parse tree information. In the second step, the 
subtype prediction of Turku Event Extraction System [35] is applied. 
For pre-processing, this system uses the Charniak-Johnson PCFG parser [40] with a self-
trained re-ranking model augmented for biomedical texts [41]. Like most teams in the 
competition, the drug entity names are replaced with a generic string to ensure the 
generality of the approach [50]. 
This approach achieved the second rank in the competition, with 0.61 F-Measure on the 
DDI-DrugBank test dataset and 0.35 F-Measure on the DDI-Medline test dataset. 
The UTurku team [51] developed a machine learning system based on the Turku Event 
Extraction System (TEES) [35]. TEES is an NLP tool for event and relation extraction 
based on SVM. It considers part-of-speech tags, dependency chains, dependency path N-
grams, entities, and external resources such as hypernyms in WordNet. For this task, 
Bjorne et al. used deep syntactic parsing to generate large graph-based feature sets. They 
parsed the corpus with TEES and extracted most of their syntactic features from the 
shortest path of dependencies between two main drugs, such as N-grams and governor–
dependent information for dependencies.  
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The significant difference between this system and the others is in using external 
resources. This system derived some features from external resources such as DrugBank 
and MetaMap. They trained three systems with different sets of features:  
1. Features extracted from the text as baseline  
2. Adding extracted features from DrugBank to the baseline  
3. Adding extracted features from MetaMap to the baseline.  
Their results showed that the external features, especially from DrugBank, increased the 
performance, because they extracted DDIs from DrugBank and used them as a feature in 
the system. However, MetaMap didn’t improve the performance, although their results 
show that MetaMap is useful for the Drug NER task. 
They obtained 0.61 F-Measure on the DDI-DrugBank test dataset and 0.23 F-Measure on 
the DDI-Medline test dataset. 
The NIL-UCM team [52] presented a SVM classifier with a linear kernel and a rich set of 
lexical, morphosyntactic and semantic features. They experimented with two approaches. 
In the first approach, they extracted and classified all DDIs in one step, as a 5-class 
classification problem. But in the second approach, they extracted DDIs in one step, and 
then classified them into 4 DDI classes in the next step. Most of the teams in the 
competition applied the second approach, separating the extraction step from the 
classification step.  
Features in this system included word features (such as words between drugs, three words 
before first drug, and so on), morphosyntactic features (such as POS), constituency parse 
tree features (such as shortest path between drugs, shortest path between first token in the 
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sentence and first drug, etc.), conjunction features, verb features, and negation features. 
They applied feature selection approaches and information gain ranker for selecting the 
best features.  
Only this team separated the DrugBank data from the Medline data and trained two 
separate SVM systems for each. However, this approach didn’t obtain a good overall 
result compared to the other approaches. 
A better result was obtained with the second approach, which separated the extraction 
phase from the classification phase. Like the other teams, they obtained a better result on 
the DrugBank data rather than the Medline data. The authors attribute the reason for the 
poorer performance to the fact that the Medline corpus has fewer words as compared to 
the DrugBank corpus. This is also suggested by Chowdhury et al. [38]. 
In this system, Paice/Husk Stemmer [53], Stanford parser [42], NegEx7 and Weka [54] 
are used. Their F-Measure on the DDI-DrugBank test dataset is 0.56 and on the DDI-
Medline test dataset is 0.12. 
The system presented by the UC3M team [25] is based on shallow linguistic (SL) kernel 
methods. The system contains three steps: pre-processing, DDI extraction, and DDI 
classification. They submitted two runs to the competition. The first run was based on 
linguistic information and the second one on semantic information. For the pre-
processing step, GATE analyzer8 and Stanford parser [42] are applied to obtain POS and 
lemmatization. Also, multiword entities are pre-processed to keep words related to same 
                                                
7 http://code.google.com/p/negex/ 
8 http://gate.ac.uk. 
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concept together. For example, they unified “beta-adrenergic receptor blocker” into a 
singleton word “beta-adrengic_receptor_blocker” as type NNP, whereas the Stanford 
parser would have processed the phrase with three different tags and phrase labels. For 
the third step, they trained four systems for each class. The only semantic information 
used is the ATC code value. They obtained a higher result with the system that used 
linguistic information. However, because they just explored one semantic feature, we 
can’t conclude anything about the (non-)importance of using semantic information for 
this task. They obtained 0.56 F-Measure on the DDI-DrugBank test dataset and 0.26 F-
Measure on the DDI-Medline test dataset. 
Our team, UWM-TRIADS [55], presented a system based on SVM and rule-based post-
processing. We explored two approaches, one separating DDI extraction from DDI 
classification, and the other doing both in one step. We obtained a better result from the 
first approach, with a two-stage classifier. We used SVM as the classifier in both stages. 
Because of the unbalanced distribution of the classes, we assigned different weights to 
each class. Our SVM features exploited stemmed words, lemmas, bigrams, part of speech 
tags, verb lists, and similarity measures, among others.  
Also, we developed a set of post-processing rules after each stage. The post-processing 
rules improved our results. 
In this system, we used LibSVM [56], Weka [54], Stanford NLP tool [42], [57], Dragon 
toolkit [58] and WordNet [59].   
We obtained 0.48 F-Measure on the DDI-DrugBank test dataset and 0.34 F-Measure on 
the DDI-Medline test dataset. 
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The SCAI team [60] presented a machine learning system which utilizes lexical, syntactic 
and semantic feature sets. Like the other teams, this system contained two steps, 
extracting DDIs and classifying DDIs. This system used an ensemble classifier in the first 
step, but for the second step, it just applied some post-processing rules. 
The set of features for the classifier contained lexical, syntactic dependency, and 
semantic features. Their feature set contained most of the features that are used by the 
other teams, also considering negation words in sentences. LibLINEAR, Naïve Bayes and 
Voting Perceptron classifiers are used in the ensemble method. After extracting DDIs, 
they applied a post-processing step to classify DDIs into 4 classes. For this step, they 
generated 4 lists of relation trigger words, manually. Different priorities are assigned to 
each class, for cases when a sentence contained trigger phrases from different classes. 
They achieved 0.46 F-Measure on the DDI-DrugBank test dataset and 0.26 F-Measure on 
the DDI-Medline test dataset. They used a rich set of features in the first step; this poor 
result shows that using only post-processing rules for classifying DDIs is not a good 
approach. 
The UColorado-SOM team [61] presented a machine learning system based on SVMs. 
Morphosyntactic, lexical and semantic features were used to train the system. They 
approached the task as a binary classification task by applying one-vs-all multi-class 
classification techniques. In essence, the system extracted and classified DDIs at the same 
time, which appears to be the reason for the poor result. 
LIBSVM [56], GENIA, TEES [35] and OpenDMAP [62] are used in this system. They 
obtained 0.42 F-measure on the DDI-DrugBank test dataset and 0.27 F-measure on the 
DDI-Medline test dataset. 
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2-3-3 Other Approaches 
In contrast to the classification of DDIs in the shared task competitions, there are several 
studies that classify DDIs in terms of their “mechanism of interaction”, distinguishing 
between Pharmacodynamic (PD) interactions and Pharmacokinetic (PK) interactions. 
Pharmacodynamic interactions include the concurrent administration of drugs having the 
same (or opposing) pharmacologic actions, and alteration of the sensitivity or the 
responsiveness of the tissues to one drug by another. Many of these interactions can be 
predicted from knowledge of the pharmacology of each drug. The change in an 
organism's response on administration of a drug is an important factor in 
pharmacodynamics interactions. Pharmacokinetics refers to the study of the absorption, 
distribution, metabolism and excretion (ADME) of bioactive compounds in a higher 
organism. In a Pharmacokinetics interaction, modifications in the effect of a drug are 
caused by differences in the absorption, transport, distribution, metabolization or 
excretion of one or both of the drugs compared with the expected behavior of each drug 
when taken individually.  
Tari et al. [63] evaluated a rule-based algorithm for extracting pharmacokinetic DDIs 
from papers and abstracts in the scientific literature. In this study, the authors 
distinguished between explicit DDIs (statements indicating a direct observation of a PK 
effect from a given drug combination) and implicit DDIs (DDIs that can be inferred 
based on claims about drug metabolic properties extracted from scientific texts). The 
algorithm was run over more than 17 million Medline abstracts and the output DDIs were 
compared with DrugBank drug interactions. The recall of the algorithm was very low, but 
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their study showed that 78% of the DDIs extracted were valid. These results illustrated 
that DDIs in DrugBank aren’t complete. 
Boyce et al. [64] presented a tool to extract PK DDI. They manually created a corpus of 
Federal Drug Administration approved drug package insert statements, containing 592 
PK DDI. Then they implemented and evaluated three different classifiers using machine-
learning algorithms. Besides classifying PK DDI in the corpus, their system classified 
statements by their modality. They evaluated SVM, Jrip, and J48, and their best result 
was 0.859 F-measure with SVM. 
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3-1 Introduction 
In this chapter, we describe our approach to extract and classify drug interactions from 
biomedical text. Our system classifies each drug pair into 5 classes – advise, effect, 
mechanism, int and none. A major challenge in this task is posed by the unbalanced 
distribution of the classes. First, considering just the positive vs. negative classes, just 
19.3% (4037/20854) of drug pairs are in the positive class. Furthermore, the four types 
within the positive class are also unbalanced, with the int type constituting only 4.6% 
(188/4037) of the instances. A classifier trained on this data will, therefore, be biased 
towards the majority class(es). To handle this problem, we propose a two-stage 
classification approach. 
In the following sections, we provide details about our approach and discuss its 
advantages, including pre-processing steps, the set of features explored in our machine 
learning method, and the post-processing rules developed for further manipulation of the 
result of machine learning.  
3-2 Pre-processing Steps 
Before classification, all sentence instances in the corpus were pre-processed in order to 
clean and normalize the corpus as well as to extract features for machine learning. We 
utilized existing NLP tools for several steps in the pre-processing. The following steps 
describe the pre-processing: 
• All letters were changed to lower case. 
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• All drug names were normalized by replacing them with one of two strings; one used 
for drug mentions that were candidates for classification in the instance (main drugs), 
and the other used for all other drug mentions (additional drugs).  
• All numbers were normalized by replacing them with the same string. 
• Sentences with less than two drug names were removed, since the system is tasked 
with detecting and classifying drug interactions between two drugs. 
• Stop words and punctuation were removed. We used different stop word lists to 
compare how the number of stop words affect the system. However, as stop words 
between two main drugs can contain useful information as an indicator for 
interaction, stop words in this context were retained. 
• Part of speech (POS) tags were obtained with the Stanford NLP tool [57].  
• Words were stemmed with the Porter Stemmer [65].  
• Words were lemmatized with Dragon tool [58]. 
• Synsets for words were obtained using WordNet [59]. 
• We developed and implemented a tool to detect negations in sentences. The tool 
highlights negated sentences and also identifies negation indicators such as not. The 
negation tool will be described later below. 
• Phrase structure parse tree of sentences were obtained with the Stanford NLP tool 
[42]. We explored multiple types of information from parse trees as features in the 
classifier, including syntactic path between the main drugs and whether or not both 
main drugs appear in the same clause.  
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3-2-1 Negation detector 
The Negation Detector tool mentioned above was developed by us. It utilizes the 
machine-learning approach of Hidden Markov models (HMMs). Hidden Markov Model 
is the stochastic analog of finite state automata. An HMM is defined by a set of states and 
a set of transitions between them. Each state has an associated emission distribution, 
which defines the likelihood of a state to emit various tokens. The transitions from a 
given state have an associated transition distribution, which defines the likelihood of the 
next state, given the current state.  
We generated a HMM and trained the negation detection model with the BioScope9 
corpus [66]. We used a java implementation of HMM, called Jahmm10. The BioScope 
corpus consists of medical and biological texts annotated for negation and speculation, 
with the annotation encoding negation and speculation keywords and their scopes. It 
contains more than 20,000 manually annotated sentences from clinical notes and 
published biological articles. For our negation detector tool, we only considered the 
negation annotations of the corpus. 
A HMM model is trained via sequences of observations. In our model, we considered 
POS tags as observations. In particular, we replaced all non-negated words with POS tags 
and generated the sequences of observations. Figure 3-1 shows our HMM model. It has 
two states, positive and negative and includes 72 observation, 35 POS tags and 37 
negated words. The accuracy of the system is 96.44% and F-measure is 92.03% in 
negation sentence detection. 
                                                
9 http://www.inf.u-szeged.hu/rgai/bioscope 
10 https://code.google.com/p/jahmm/ 
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Figure 3-1: This Hidden Markov Model is used in the negation detector system. This HMM consists two 
states, positive and negative. Each rectangle shows one of observations that can be a POS tag or a word that 
appeared in the negated parts of the sentences. 
3-3 Two-stage classification 
The architecture of our system is illustrated in Figure 3-2. The system comprises two 
classifiers in separate stages. In the first stage, we train a binary classifier to classify drug 
pairs into positive and negative classes. Then, in the second stage, we consider only those 
instances that are classified as positive by the first classifier, and classify them into one of 
four types within the positive class – advise, effect, mechanism, and int – using a multi-
class classifier.   
A two-stage classifier offers a distinct advantage over a one-stage classifier for the DDI 
data set, not just because it is highly skewed towards one class – the negative class – but 
also because this majority class is clearly semantically distinct from the other positive 
classes. Therefore, by reframing part of this problem as a binary classification task, we 
can exploit binary classification techniques and allow the classifier to be particularly attentive to 
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features distinguishing positive and negative drug pairs, while at the same time avoiding the bias 
against each of the non-majority classes. Our experiments with the training set confirm this idea. 
Using a two-stage classification approach also allows us to explore different classifiers 
for each stage and find the best fit for each of them separately, by pursuing advantageous 
approaches for binary classification on the one hand and multi-class classification on the 
other hand.  
After pre-processing, the remaining sentences contain two or more drugs. In the first 
stage, we need a binary classifier to classify each drug pair as positive or negative. The 
following is an example of a sentence with drug names highlighted. 
• “Catecholamine-depleting drugs, such as reserpine, may have an additive effect 
when given with beta-blocking agents.” 
As the sentence has three drug names, the system needs to consider DDI between the 
following three drug pairs: 
1- Catecholamine-depleting drugs and reserpine 
2- Catecholamine-depleting drugs and beta-blocking agents 
3- reserpine and beta-blocking agents 
At this point, the DDI extraction task is carried out via a binary classifier. If the classifier 
predicts a DDI between a pair, then it classifies the pair as positive, and otherwise as 
negative. As we want to pass only the positively classified instances from the first stage 
to the second stage classifier, we favor the positive class in the first stage. For this 
purpose, if the classifier allows us to assign weights to each class (e.g., SVM) we assign a 
high weight to the positive class. This results in a relatively high number of false 
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positives for the positive instances, which we attempt to reduce with a set of post-
processing rules before sending them to the second stage classifier. 
 One/More instances 
Pre-Processing 
POS tagger 
Stop Words list Lemmatizer 
Stemmer 
Sentence with more than two 
drugs 
Final Classification 
Post-Processing  
Post-Processing 
Instances classified as 
positive 
First Stage Classifier 
(Binary Classifier) 
Second Stage Classifier 
(Multi-Class) 
Classified as positive Classified as negative 
Figure 3-2: DDI Extraction and Classification System architecture.  
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We should add that for training the first classifier we used all the instances in the corpus 
but for training the second classifier, we just used the positive instances that classified 
into Advice, Effect, Mechanism, and Int. 
 3-3-1 Features 
To train the classifiers, we utilized a variety of features to investigate their effectiveness 
and choose the best combination of features for classification. In this section, we explain 
these features by separating them into two categories: features per sentence and features 
per drug-pair instances. Recall that since one sentence can have more than two drug 
names, an instance of the sentence is generated for each drug pair.  
Features per sentence 
These are sentence-level features that have the same values across all instances of a 
sentence. 
• Words: This is a binary feature for all words that appeared more than once in the 
corpus, indicating the presence or absence of each such word in the sentence. We 
considered stemmed words as well as lemmatized words.  
• Mutual Information [67]: Instead of using all words that appeared in the corpus, 
we apply mutual information as a feature selection approach to choose 
informative words. Mutual information for term t and class c is calculated with 
the following formula:  
 
P t, c = N!,!N ∗ log!!!,!∗!!!∗!!    + N!,!N ∗    log!!!,!  ∗!  !!∗!!  
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+ N!,!N ∗ log!!!,!∗!!!∗!!    + N!,!N ∗    log!!!,!  ∗!  !!∗!!    
 
Where, N: Number of all instances, N!,!: Number of instances in c that contain t, N!,!: Number of instances that contain t but not in the class c, N! : Number of 
instances that contain t, … We rank the words based on the Mutual Information 
score and use 100/200/500/1000 top words. 
• Word bigrams: This is a binary feature for all word bigrams that appeared more 
than once in the corpus, indicating the presence or absence of each such bigram in 
the sentence 
• Number of words: This feature represents the total number of words in the 
sentence 
• Number of drug mentions: This feature represents the total number of drug 
mentions in the sentence.  
• Cosine similarity between centroid vector of each class and the instance: 
Inspired by the vector space [67] Information Retrieval approach, we add new 
features to represent the cosine similarity between a sentence and the centroid of 
normalized vectors for sentences assigned the class C. Cosine similarity is 
calculated based on modified tf*idf. We compute modified tf*idf for a word w, 
based on the following formula: 
Tf ∗ idf = Count w  in  instance ∗    log! !"#$%&  !"  !""  !"#$%"&'#!"#$%&  !"  !"#$%"&'#  !"#$%&#   ! !!  
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TF is the number of times the word occurs in the instance. IDF is the logarithm of 
number of all instances divided by the number of instances that contain the word. 
To calculate the centroid vector for class C, a vector is created for each instance in 
class C by giving each word in the instance a modified TF*IDF weight. The 
centroid vector for class C is the mean of all vectors of sentences in class C. The 
cosine similarity between a given instance and the centroid vector of each class is 
then used as a feature. 
Features per instance (each pair) 
In contrast to sentence-level features, these features may have different values across the 
different drug-pair instances. In each instance, we distinguished the two main drugs of 
interest for the instance from all other additional drugs mentioned in the instance. 
• Number of words between two main drugs: This represents the total number of 
words between the two main drugs.  
• Number of drugs between two main drugs: This represents the total number of 
additional drugs appearing between the two main drugs. 
• Number of verbs: We use the number of verbs in the instance as a feature, but 
relative to their sentential position. In particular, we split each instance into three 
sections: (i) before the first main drug, (ii) between the two main drugs, and (iii) 
after the second main drug. Then, we count the number of verbs in each section, 
and use them as three different features. 
• Number of verbs using class-specific verb lists: For each class, we extract two 
lists of verbs. The first list contains verbs that appeared in just that class but not in 
the others. Thus, the set of verbs extract for each class are unique and different 
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from the verbs associated with other classes. The second list includes all verbs 
that appeared in that class and their synonyms, extracted from WordNet. Then, for 
each of the three sentence sections, as described above, we create two features to 
represent the number of verbs from each of these lists that appeared in the section.  
• POS of words between two main drugs: This is a binary feature for word POS 
tags obtained from POS tagging, and indicates the presence or absence of each 
POS between the two main drugs. 
• Path between two main drugs: Path between two main drugs in the parse tree is 
another feature in our system. Because syntactic paths are in general a sparse 
feature, we reduced the sparsity by collapsing identical adjacent non-terminal 
labels. E.g., NP-S-VP-VP-NP is converted to NP-S-VP-NP. This technique 
decreased the number of paths by 24.8%. 
• Negation: To consider negation in the instance, three features are defined that 
respectively indicate negation before the first main drug, between two main drugs, 
and after the two main drugs. 
• Clause Boundary: This feature shows that both main drugs are in the same 
clause or not. The system utilizes the parse tree to set the binary value for this 
feature.  
3-3-3 Post processing 
As described before, we have two sets of post-processing rules for each stage of the 
system. Here, we describe these rules, developed on the basis of observations in the 90% 
of the competition training data (that was used as the training set in our experiments). In 
the next chapter, we evaluate the effectiveness of these rules.  
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3-3-3-1 Post-processing after the first stage 
Post-processing rules for the first stage were designed to reduce the number of false 
positives for the positive class, since the weight assignment in this stage favors this class. 
The following describes the rules, with examples:  
1. An instance is classified as negative if both drug mentions have the same name, 
since a drug cannot interact with itself. In the following instance, one drug is 
appeared twice. So, the system considers them as a drug pair. If the classifier in 
the first stage classifies them as positive, the post-processing step updates its label 
to negative. 
• “In controlled clinical trials of AUGMENTIN XR, 22 patients received 
concomitant allopurinol and AUGMENTIN XR. 
2. An instance is classified as negative if one of the drugs is a plural form of the 
other one, since, as above, they refer to the same drug.   
• “Oral Anticoagulants: Interaction studies with warfarin failed to identify 
any clinically important effect on the serum concentrations of the 
anticoagulant or on its anticoagulant effect.” 
3. An instance is classified as negative if one of the drug mentions refers to a drug 
class name of the other, since we don’t expect a drug to interact with its own class 
as a whole. Drug class names were obtained from a table provided by the FDA.11 
In the example below, “MAOI” is the drug class name for “isocarboxazid”.  
                                                
11http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm 
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• “You cannot take mazindol if you have taken a monoamine oxidase 
inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine 
(Parnate), or phenelzine (Nardil) in the last 14 days.” 
4. An instance is classified as negative if “,” or “, and” appears between the two 
main drug mentions, and is accompanied by an additional drug mention. The rule 
identifies contexts where drugs are mentioned as a set, in interaction with a 
different drug. The following sentences show “glyburide”, “tolbutamide” and 
“glipzide” as part of a set of drugs in interaction with the additional drug 
“DIFLUCAN”.  
• “DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and 
glipizide and increases the plasma concentration of these agents.”  
• “DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and 
glipizide and increases the plasma concentration of these agents.” 
5. An instance is classified as negative if “,” and additional drugs appear between 
the main drug mentions. Like the previous rule, this again recognizes drugs 
mentioned as a set, but in particular, identifies non-adjacent mentions. For 
example, the following sentence doesn’t express any interaction between 
“tolbutamide” and “glipizide”, and the rule recognizes them as part of a set 
mention even though they are non-adjacent. 
• “DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and 
glipizide and increases the plasma concentration of these agents.” 
6. An instance is classified as negative if “or” appears between the two main drug 
mentions and the sentence contains additional drug mentions. The presence of 
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additional drug mentions in the sentence is required here since such conjoined 
pairs can interact with each other when they occur alone.  
• “Concurrent ingestion of antacid (20 mL of antacid containing aluminum 
hydroxide, magnesium hydroxide, and simethicone) did not significantly 
affect the exposure of oxybutynin or desethyloxybutynin.” 
3-3-3-2 Post processing after the second stage 
Post-processing after the second classifier identifies sentences like the following: 
• “Coadministration of alosetron and strong CYP3A4 inhibitors, such as 
clarithromycin, teli thromycin, protease inhibitors, voriconazole, and 
itraconazole has not been evaluated but should be undertaken with 
caution because of similar potential drug interactions.” 
Examples like these illustrate that if drugs are mentioned as a set, then all drugs in the set 
must have the same interaction type with a drug mentioned outside the set. Thus, in the 
example, the interaction of each of “clarithromycin”, “telithromycin”, “protease 
inhibitors”, “voriconazole”, and “itraconazole” with “alosetron” should be classified in 
the same way. We use several syntactic and lexical cues to identify set mentions of drugs. 
Then, since the classifiers can make different decisions for each such pair (e.g., it may 
assign one label to the interaction of “clarithromycin” with  “alosetron” and another label 
to the interaction of “telithromycin” with “alosetron”), we apply uniform labeling for the 
interaction of all such pairs. The majority label was used as the common label. Ties were 
not encountered in this data, although a solution would have to be devised otherwise. 
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An important consideration for this rule is that it uses both positively and negatively 
labeled instances. The former are taken from the result of the second stage classifier, and 
the latter from the negative instances of the first stage classifier and the negative 
instances of the first post-processor. These varied inputs to the rule are illustrated by the 
three ingoing arrows into the second post-processor in Figure 3-2.  
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4-1 Introduction 
In this chapter, we first present our implementation of the system, including the libraries 
and tools that we utilized. Metrics used to evaluate system performance are then 
presented, followed by the results, where we also discuss the impact of various features 
on the system using SVM. Then, the performance of different classifiers in each of the 
two system stages is evaluated and the best system introduced. We also present results of 
applying the post-processing rules to the output of each stage. We finish with the error 
analysis, conclusions, and discussion of future work.  
4-2 Implementation 
As there are many Natural Language Processing and Machine Learning tools and 
libraries in Java, we used this programming language to implement our method. Some of 
these tools such as Weka [54] are applied in classification tasks, but Weka is not designed 
to directly handle the steps in our system architecture, which consists of two classifiers 
with the output of the first classifier serving as input to the second one, and a set of post-
processing rules applied after each stage. Therefore, we implemented a tool that, besides 
using available NLP libraries, handles our two-stage approach for classification.  
The following lists and describes the existing libraries and tools utilized in our system. 
(These were also mentioned briefly in Chapter 3.) We have used these tools for various 
tasks in our system, including machine learning, pre-processing, and feature extraction. 
• Weka: Weka [54] is a collection of machine learning algorithms available as a 
java-based software package, with graphical user interfaces providing easy access 
to its functionalities. We used Weka to apply some of its classifiers in our method. 
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The input to Weka has to be in a specific format, called the Attribute-Relation 
File Format (Arff). An Arff file is a text file created by declaring all attributes 
(i.e., the feature names) in the file, followed by a list of the data instances. Each 
instance is represented as a vector of values for the attributes, with one value 
provided for each attribute. The last value of the instance vector indicates the 
class label of the instance. To utilize Weka for training our classifiers, we created 
an Arff file using the instances in the data and the features described in Chapter 3.   
• LibSVM [56]: LibSVM is software library for Support Vector Machines, 
implemented in Java, that allows users to apply SVM for their applications. We 
used this library to train the SVM classifier. 
• Stanford NLP tool: This library is used to obtain POS tags [57] and parse trees 
[42] for sentences. The tool contains several NLP algorithms such as part-of-
speech (POS) tagger, named entity recognizer (NER), parser, and the coreference 
resolution system. It is provided in different languages such as Java, Perl, Python, 
Ruby, Sacala, and Clojure. 
• Porter Stemmer [65]: This is a library used for stemming words in the sentences. 
Stemmed words were used as a feature in our classifier. 
• Dragon tool [58]: We used this tool to obtain word lemmas, which were used as a 
feature in our classifier.  
• WordNet [59]: As described in Chapter 3, we created a list of synonyms for verbs 
in each class.  We used WordNet to obtain synonyms. 
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4-3 Metrics 
We used the standard metrics of Precision, Recall, and F-measure to evaluate the 
performance of our system. To compute these metrics, the organizers of the 
DDIExtraction 2013 Challenge provided a code in Java that takes as input a text file of 
predictions and calculates the precision, recall and F-measure. In these metrics, a DDI is 
correctly detected if the system assigned the correct class label to it. A prediction is 
correct if both extraction label (Yes, None) and classification label (Advise, Mechanism, 
Effect, Int) are correct. To clarify the meaning of these metrics, let’s look at the meaning 
of precision for type Advise: 
Precision =    TPTP+ FP 
TP indicates the true positives, i.e., the number of truly detected pairs of the advise class 
class and FP indicates the false positives, i.e., the number of pairs that are predicted as 
advise incorrectly.  
For each run in the results discussed below, we present these three metrics. F-measure is 
calculated with the macro-averaged method12, i.e., by taking precision to be the average 
of the precision calculated for each type, and similarly for recall.  
4-4 Results 
In our experiments, we first explored different combinations of features (described in 
Chapter 3) with SVM in order to identify the best performing feature set. We then used 
this feature set to further explore the performance of additional classifiers, thus 
                                                
12  http://www.cs.york.ac.uk/semeval-2013/task9/data/uploads/semeval-2013-task-9_2-
evaluationmetrics.pdf 
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identifying the best machine learning classifier for the task. Post-processing rules were 
applied to the output of the best performing classifier. As the test set had not been made 
available until the time of writing of this thesis, the experiments we conducted after the 
challenge are done by using only the training data, by splitting the training data into a 
training set (90%) and a test set (10%). In this section, we present and discuss the results 
of all our experiments. For each experiment, precision, recall and F scores are given. 
4-4-1 Feature Selection 
To determine which features are most useful in the system, we added them incrementally 
to our classifiers and examined their effect on system performance. We used SVM for 
identifying the best performing features, in both stages of the system.  
In the first experiment, we explored the role of words as features. We compared the effect 
of using all words as features with using only informative words, where informative 
words are chosen by calculating the Mutual Information (MI) score for words in each 
class (described in 3-3-1). We further explored different cut-offs for choosing informative 
words in each class with high MI score: 100, 200, 500 and 1000, which yielded 296, 476, 
940, and 1417 unique words, respectively, as features. Table 4-1 presents the results for 
this experiment. The first row shows the result with all words used as features, whereas 
the remaining rows show the result of using informative words as features.  
Table 4-1: Results of using words with high mutual information score compared to all words.  
Features # Of features Precision Recall F-Measure 
All Words 1599 0.22 0.74 0.34 
100 words of 
each class with 
high MI 
296 0.33 0.68 0.34 
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200 words of 
each class with 
high MI 
476 0.32 0.68 0.34 
500 words of 
each class with 
high MI 
940 0.28 0.70 0.34 
1000 words of 
each class with 
high MI 
1417 0.30 0.74 0.37 
 
As Table 4-1 illustrates, using informative words to train the classifiers performs better 
than using all words. Furthermore, with informative words, the best result was obtained 
with 1000 words. Therefore, in all remaining experiments, we used 1000 words of each 
class with high MI score, with a total of 1417 unique words. 
In the next experiment, we evaluated the impact of POS as a feature in combination with 
the 1000 high MI words. POS is a binary feature for word POS tags and indicates the 
presence or absence of each POS between the two main drugs. The second row of Table 
4-2 illustrates the results of adding the POS feature. The first row repeats the scores for 
the best result from Table 4-1, The second row shows that adding POS markedly 
increases the F-Measure from 0.37 to 0.59, suggesting that POS is a highly useful feature. 
In the next set of experiments, we evaluated the impact of adding additional features 
individually to the combination of the high MI words and POS features. 
 
Table 4-2: System performance for different sets of features 
Features Precision Recall F-Measure 
1000 words with high MI 0.30 0.74 0.37 
1000 words with high MI 
+POS 
0.48 0.83 0.59 
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1000 words with high MI 
+POS 
+Verb features 
0.45 0.80 0.56 
1000 words with high MI 
+POS 
+Numbers features 
0.38 0.75 0.50 
1000 words with high MI 
+POS 
+Path Between drugs 
0.42 0.71 0.51 
1000 words with high MI 
+POS 
+BiGrams 
0.34 0.78 0.46 
1000 words with high MI 
+POS 
+Negation 
0.45 0.83 0.58 
1000 words with high MI 
+POS 
+Cosine Similarity 
0.48 0.83 0.59 
1000 words with high MI 
+POS 
+Clause Boundary 
0.45 0.80 0.56 
 
Verb features, shown in the third row, represents the number of verbs in the sentence, and 
the number of verbs from each class-specific verb list (discussed in Chapter 3). As can be 
seen in the table, the F-Measure dropped by 0.03% after adding these features to the 
system. 
The fourth row of Table 4-2 shows the impact of number features on the system. The 
number features contain three features, the number of words in the sentence, the number 
of words between main drugs, and the number of drug names in the sentence. The result 
indicates that number features decreased the system performance.  
One of the features we explored was path between main drugs in the parse tree, shown in 
the sixth row of the table. We traversed the parse tree to extract the path between the 
main drugs, while reducing the length of the path by collapsing identical adjacent non-
terminal labels. Using this feature decreased the performance by 0.08.  
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The next experiment explored the effect of using Bi-grams as feature in the classifiers. 
For each word Bi-grams that appeared more than once in the corpus, we assigned a 
feature to show the presence or absence of the bi-gram in the sentence. The sixth row of 
Table 4-2 presents the results, highlighting that adding Bi-grams to the system decreased 
the F-Measure. 
One of our explored features was negation. We added three features to the classifiers that 
indicated presence of negation in different parts of sentence: before the first drug, 
between two main drugs, and after the second drug. The results are presented in the 
seventh row of Table 4-2. This feature decreased the F-Measure from 0.59 to 0.58. 
We also explored the Cosine similarity feature that presented the cosine similarity 
between a sentence and the centroid vector of each class. The eighth row of Table 4-2 
shows the performance of the system after adding this feature. Unlike the other features, 
this feature didn’t decrease the performance of the system. But it did not increase the F-
Measure either, so we decided not to use this feature in the final system. 
The last explored feature is Clause Boundary, which indicates whether main drugs are in 
the same clause or not. The performance of the system after adding this feature is 
presented in the last row of table 4-2. It didn’t increase the F-Measure. 
After exploring different sets of features, we found that the best result is obtained with 
using 1000 words with high Mutual Information together with part of speech tags. In the 
following experiments, therefore, we used this set of features to explore additional 
classifiers. 
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4-4-2 Classifier Selection 
Given the best set of features, we explored 6 different classifiers for each stage: Naïve 
Bayes, Multinomial Naïve bayes, J48, Jrip, Random forest, and SVM. To find the best fit 
for the first stage classifier, we used SVM as the classifier in the second stage, and 
evaluated all the classifiers in the first stage. The results in Table 4-3 illustrates that SVM 
is the best fit for the first stage based on its F-Measure. It is worth noting, however, that 
with Random Forest, the precision was 30% more than with SVM. Therefore, for a 
system aiming at high precision, Random Forest would be the best choice for this stage. 
We note that to handle the unbalanced class problem, we explored different approaches 
and algorithms, including SMOTE [68] and other resampling algorithms, but they were 
not  effective. Instead, we found that assigning weights to the classes in SVM was more 
effective. Therefore, we learned the best weights for each class, based on cross-validation 
over the training set. In the first classifier, we assigned weight 1 to the None class and 6.5 
to the positive class. In the second classifier, the best weights were 800, 600, 3200, and 
500, respectively, for advise, effect, int, and mechanism. 
Table 4-3: System performance for different classifiers in the first stage 
Classifier in the 
first stage Precision Recall F-Measure 
Naïve Bayes 0.20 0.72 0.31 
Multinomial Naïve 
bayes 0.32 0.60 0.41 
J48 0.69 0.50 0.57 
Jrip 0.75 0.36 0.48 
Random forest 0.78 0.45 0.56 
SVM 0.48 0.83 0.59 
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We ran the same experiment for finding the best classifier for the second stage. In these 
experiments, SVM is used as the classifier in the first stage and the best features are 
utilized to train the classifiers. Table 4-4 illustrates the results of these experiments. As 
the results show, we obtained the best F-measure by using SVM in the second stage. 
Table 4-4: System performance for different classifiers in the second stage 
Classifier in the 
second stage Precision Recall F-Measure 
Naïve Bayes 0.30 0.59 0.39 
Multinomial Naïve 
bayes 0.41 0.68 0.48 
J48 0.36 0.75 0.48 
Jrip 0.36 0.72 0.48 
Random forest 0.47 0.69 0.51 
SVM 0.48 0.83 0.59 
 
4-4-3 Impact of Post-Processing 
After finding the best set of features and classifiers, we explored the impact of the post-
processing rules. We developed two sets of rules -- one applied after the first stage and 
the second on the final results. Table 4-5 presents the results, showing that using post-
processing rules increased the F-measure. A larger increase is observed with the first 
stage rules, which may be attributed to the larger number of rules that are likely to have 
covered more examples.  
Table 4-5: Impact of post-processing rules. 
Post-processing Precision Recall F-Measure 
None 0.48 0.83 0.59 
After the first stage 0.53 0.82 0.63 
On the final results 0.53 0.80 0.62 
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After the first stage 
+On the final results 
0.55 0.80 0.64 
 
4-4-4 Class-wise Performance 
Apart from the overall results given above, it is also useful to examine the class-wise 
performance of the system. This is given in Table 4-6. What is interesting to observe is 
that the “Int” class shows the highest F-measure, even though this class had the fewest 
instances in the training data. The hardest class to identify was the Mechanism class, 
which is probably due to its confusability with the Effect class, which also shows a lower 
F-measure compared to Int and Advise.  
Table 4-6: Class-wise Precision, Recall, and F-Measure 
Type Precision Recall F-Measure 
Advise 0.53 0.80 0.64 
Effect 0.46 0.77 0.57 
Mechanism 0.32 0.74 0.45 
Int 0.88 0.88 0.88 
 
4-4-5 Stage 1 Performance 
 All results above present the performance of the system after the second stage 
classification. But it is also useful to assess the performance of the first stage 
classification alone, as it provides insight into the task of DDI identification, i.e., 
classification as positive vs. negative. For this task taken alone, the precision, recall, and 
F-Measure after applying SVM and post-processing were 0.48, 0.86, and 0.61 
respectively. The low precision relative to recall seen here is not surprising since the 
positive class was assigned a higher weight. However, what is interesting is that although 
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the impact of the first stage post-processing on the overall result was significant (Table 4-
5), it’s absolute impact on the precision in the first stage is obviously not strong enough. 
As we discuss in the error analysis later in this chapter, there is much room for improving 
the precision in the first stage with better post-processing.  
4-4-6 Comparison with the competition system 
Since our submitted system to the DDIExtraction-2013 challenge used a different 
combination of features, we compared its performance with our current system. As 
shown in Table 4-7, the F-measure in our new system is 12% higher than the competition 
system. This comparison shows the effect of careful feature selection carried out for our 
current experiments, which we were not able to carry out for the competition system due 
to time constraints. In the competition system, we used a large number of features, given 
lack of knowledge about which particular features might be most effective. 
We note that comparison of our augmented system with the other systems from the 
competition is not possible because of the unavailability of the challenge’s evaluation test 
set until the time of writing of this thesis.   
Table 4-7: Comparison of best system with DDIExtraction-2013 competition system 
Features Precision Recall F-Measure 
The best system 
(1000 words with high MI 
+POS) 
0.55 0.80 0.64 
The competition system (All words + 
BiGrams 
+ POS + Verb 
+Number features +Cosine Similarity) 
0.52 0.73 0.52 
 
  
52 
4-5 Error Analysis 
As the results above show, the F-Measure of our system is not very high, but this was 
true of all the systems in the competition. To some extent, the poor performance in 
general can be attributed to the corpus itself, specifically to the unbalanced distribution of 
the types. This is further compounded by the unbalanced proportion of sentences from the 
two sources from where the corpus was drawn: only 6% of the sentences in the corpus 
come from Medline.  
However, for our system alone, one of the major reasons for the low F-measure was the 
assignment of a higher weight to the positive class, which resulted in a high false positive 
rate. Our error analysis shows that 87% of the errors were stage 1 errors, and that more 
sophisticated features for learning, or rules for post-processing, should be developed for 
further improvement, as discussed next. 
Some errors occurred because the post-processing rules identify grouped mentions of 
drugs based only on lexical and punctuation identifiers. Most of these errors could have 
been averted if the identification of grouped mentions also utilized syntactic information. 
For example, in the following sentence, 
• “Drugs that Lower Seizure Threshold: Concurrent administration of 
WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, 
theophylline, systemic steroids, etc.) that lower seizure threshold should 
be undertaken only with extreme caution.” 
Our current rules couldn’t detect that “theophylline” and “steroids” were mentioned in 
the same group because group identification in the current rules requires adjacency of the 
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drug names. Using syntactic constituency instead and recognizing intervening words as 
modifiers could have identified grouped mentions more systematically.  
Our analysis also revealed other features that are important to exploit, such as lexical 
semantics, scope of negation and hypothetical markers, scope of salient keywords, and 
noun phrase referential status. 
The following example shows that it may be possible to exploit the syntactic and 
semantic scope of the interaction keyword, concurrent, to the two drug names following 
it, but not the one preceding it. This example, as an instance for the two drugs, 
“etretinate” and “acitretin”, was annotated as None (no interaction), whereas our system 
labeled it as Effect.   
• “Ethanol:Clinical evidence has shown that etretinate can be formed with 
concurrent ingestion of acitretin and ethanol.” 
The next example illustrates the role of hypothetical marking and its scope. The 
interaction in question is the two drugs, “Argatroban” and “heparin”, highlighted in the 
hypothetical if-clause, which the system ought to accordingly treat as a hypothetical 
interaction and label as None. Instead, our system labeled this instance as Effect.  
• “However, if Argatroban is to be initiated after cessation of heparin 
therapy, allow sufficient time for heparins effect on the aPTT to decrease 
prior to initiation of Argatroban therapy.” 
Of course, some errors were related to the annotation. For example, PAH in the following 
sentence does not refer to a drug at all. Note, though, that even if PAH were considered to 
be a drug, the class label assigned to it seems to be incorrect, both by the annotation 
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(labeled as Effect) and the system (labeled as Advise). Unfortunately, information about 
the level of noise to be expected of the corpus isn’t available, so it is difficult to quantify 
the contribution of such errors and use it to set an upper bound on performance. 
• “Renal clearance measurements of PAH cannot be made with any 
significant accuracy in patients receiving sulfonamides, procaine, or 
thiazolesulfone.” 
4-6 Conclusions and Future Work 
In this thesis, we have presented a system to extract and classify DDI mentions from 
biomedical text. As our corpus contains a highly unbalanced class distribution, we 
applied a two-stage classifier to handle this problem. In the first stage, a binary classifier 
classified drug pairs into non-interaction and interaction classes. Then, drug pairs that 
were detected as interacting in the first stage are classified via a multi-class classifier into 
Advise, Effect, Mechanism, and Int classes. We explored various features in a selective 
way to find the best set of features for the classifier. We also experimented with six 
different classifiers in each stage to choose the best classifier for each. We further applied 
post-processing rules after each stage to improve the results. We have argued that 
handling the unbalanced class distribution is one of the advantages of our approach. In 
addition, our approach allows for using different sets of features and classifiers in the 
different stages. We learned that for this specific application, using SVM in both stages 
obtains the best F-Measure, although Random Forest in the first stage obtained 30% more 
precision than SVM. In this application, we used the same features to train both 
classifiers. The best feature set included 1000 top informative words and part of speech 
tags between two main drugs. The F-Measure of our system is 0.64, which is 0.12 higher 
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than our submitted system to the DDIExtraction 2013. This result shows the effectiveness 
of feature selection, because in the submitted system, we used a longer list of features 
without applying any feature selection approach. Unfortunately, we couldn’t compare our 
results with the other systems in the competition because the competition test set wasn’t 
available at the time of writing of this thesis.  
As future work for this thesis, we plan to: 
• Train our system on the competition training set and test on its test set 
• Use two different lists of features for each classifier: As the classifiers are 
different, binary and multi-class classifier, we will investigate different sets of 
features for each of them. We plan to exploit linguistic features in a more 
sophisticated way, including scope of negation, hypothetical marking, and salient 
keywords. 
• Add a 5th class (“None”) to the second classifier to detect some false positive 
instances generated by the first classifier. As the second classifier classifies 
instances into Advice, Effect, Mechanism, and Int, it is not able to detect false 
positive instances generated by the first classifier. So, we will add “None” class to 
this classifier and convert it into a five-class classifier. 
• Use syntactic information in addition to lexical/punctuation signals for post-
processing. 
• Explore kernel based SVM: We only used linear SVM in this thesis but we will 
explore the effect of kernel based SVM. 
• Explore ensemble classification in both stages.  
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• Train two separate systems for Medline and DrugBank sentences: Since 
DrugBank and Medline exhibit different structures in their sentences and 
documents, we expect that having separate classifiers for each will lead to better 
performance. 
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